Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Takes The Lead In Settling SEC/DoJ Foreign Corrupt Practices Act Probe

This article was originally published in PharmAsia News

Executive Summary

Johnson & Johnson agreed to pay $70 million to resolve charges by the Securities and Exchange Commission and the Department of Justice that the company bribed doctors in several European countries to order or prescribe its products in violation of the Foreign Corrupt Practices Act
Advertisement

Related Content

Attorney Richard Cassin On FCPA’s Impact On Foreign Acquisitions And Competitor Snitching: An Interview With PharmAsia News
Attorney Richard Cassin On FCPA’s Impact On Foreign Acquisitions And Competitor Snitching: An Interview With PharmAsia News
Translating The Foreign Corrupt Practices Act Into Practice: U.S. DoJ/SEC Offer Pragmatic Enforcement Guide
Pfizer Settles Foreign Bribery Charges, Wins Deferred Prosecution For Helping Government
Could Less Enforcement Action Of Foreign Corrupt Practices Act Mean Compliance Is Improving?
A Long Way Still For Corrupt Business Practices In China, India - Pharmaceutical Regulatory And Compliance Congress
Case Studies: Several Patent And Registration Litigations Highlight What Not To Do In China
Foreign Corrupt Practices Act Raises Disclosure Dilemma For Internal Investigations
J&J Separates U.S. OTCs In "Unorthodox" Reorg To Get McNeil Back On Track
Corporate Compliance Programs Are Often Inadequate To Avoid Foreign Corruption Investigations, DoJ Official Says
Advertisement
UsernamePublicRestriction

Register

SC077619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel